Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.

J Clin Oncol · 2022 · PMC9462531 · PMID 35442766

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

20 According to the hierarchical testing, OS was significantly improved with tislelizumab over chemotherapy in patients with PD-L1 TAP ≥ 10% (HR, 0.54), and in the prespecified exploratory analysis, tislelizumab also showed a favorable trend of improvement in OS versus chemotherapy in patients with PD-L1 TAP < 10% (HR, 0.82).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.